Drug Labeling Must Be Controlled By Sponsors, Not FDA, Petition Says
This article was originally published in The Tan Sheet
Executive Summary
Sponsors should have exclusive control over the "intended uses" of drugs unless exceptional circumstances exist, a Bennett, Turner & Coleman citizen petition states.
You may also be interested in...
FDA, Rx Antihistamine Makers' Next Move: Compromise?
A negotiated compromise between FDA and the manufacturers of second-generation antihistamines seems the most logical way to resolve the legal, regulatory and financial obstacles facing both sides.
Second-Generation Antihistamine OTC Labeling Could Resemble Monograph
OTC labeling for second-generation antihistamines - if the drugs were to switch - may not differ greatly from warnings on existing nonprescription allergic rhinitis symptom relief drugs.
Emergency Contraceptives OTC Access Faces Uphill Struggle
The burgeoning movement to persuade FDA to approve emergency contraceptives for over-the-counter use may have to overcome several high hurdles to succeed.